Clear Cell Renal Cell Carcinoma
Key Points
Key Points
- Kidney cancer will be diagnosed in 79,000 U.S. patients in 2022 and will account for 13,920 deaths.
- Opportunities for extended survival and even durable disease control in the metastatic setting have recently appeared as novel classes of therapeutics, reshaping the trajectory of this cancer.
- This rapid evolution has paved the way for this first set of comprehensive guidelines for treating metastatic clear cell renal cell carcinoma (ccRCC).
Diagnosis
...agnosis
...ndation 1.1The diagnosis of metastat...
....2Radiographic diagnosis of metastatic clear cel...
Treatment
Treatm...
...ommendation 2.1Select patients (see Pr...
...mendation 3.1Select patients with m...
...e 1. First-Line Treatmenta Select ca...
...commendation 3.2All patients with metas...
...n 3.3Patients with favorable risk disease wh...
Recommendation 3.4Select patients with metast...
...dation 3.5The use of high dose inte...
...rom 2023 Rapid Recommendation Update...
...3.6Treatment with IpiNivoCabo is not rec...
...ndation 4.1Nivolumab or cabozantinib s...
Recommendation 4.2Patients progres...
...ion 4.3Patients who progress after initial thera...
...mmendation 4.4For patients on immunotherapy...
...on 5.1For patients with low volume metastatic r...
...ommendation 5.2For patients undergoing compl...
...endation 6.1.1Patients with symptomatic bone...
...ommendation 6.1.2Patients with bone metastases f...
.... Second-Line or Greater Trea...
...astases-Directed Treatment...
...tion 6.1.3No recommendation regarding optimal sys...
...mendation 6.2.1Patients with brain...
...ion 6.2.2No recommendation regarding optimal s...
...n 6.3Patients with metastatic clear cell rena...
...Special Patient Subtypes...
ASCO believes that cancer clinical tria...